Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 91 articles:
HTML format
Text format



Single Articles


    September 2018
  1. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients.
    Eur J Gastroenterol Hepatol. 2018 Sep 7. doi: 10.1097/MEG.0000000000001264.
    PubMed     Text format     Abstract available


  2. STOURNARAS E, Neokosmidis G, Stogiannou D, Protopapas A, et al
    Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.
    Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001254.
    PubMed     Text format     Abstract available


  3. FUKUI A, Kawabe N, Hashimoto S, Kamei H, et al
    Skeletal muscle mass depletion in patients with hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001255.
    PubMed     Text format     Abstract available


    August 2018
  4. MUN EJ, Green P, Berry K, Ioannou GN, et al
    No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
    Eur J Gastroenterol Hepatol. 2018 Aug 23. doi: 10.1097/MEG.0000000000001242.
    PubMed     Text format     Abstract available


  5. PASSERINI M, Schiavini M, Magni CF, Landonio S, et al
    Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 22. doi: 10.1097/MEG.0000000000001239.
    PubMed     Text format     Abstract available


  6. EL-NAHAAS SM, Fouad R, Elsharkawy A, Khairy M, et al
    High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001228.
    PubMed     Text format     Abstract available


  7. GAYAM V, Tiongson B, Khalid M, Mandal AK, et al
    Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
    Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001233.
    PubMed     Text format     Abstract available


  8. ALI N, Hussain W, Hayat A, Shah T, et al
    Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients: a multicentric study.
    Eur J Gastroenterol Hepatol. 2018 Aug 3. doi: 10.1097/MEG.0000000000001220.
    PubMed     Text format     Abstract available


    July 2018
  9. SONG BG, Sinn DH, Chi S, Kim K, et al
    Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy.
    Eur J Gastroenterol Hepatol. 2018 Jul 30. doi: 10.1097/MEG.0000000000001226.
    PubMed     Text format     Abstract available


  10. ELHELBAWY M, Abdel-Razek W, Alsebaey A, Hashim M, et al
    Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment.
    Eur J Gastroenterol Hepatol. 2018 Jul 18. doi: 10.1097/MEG.0000000000001215.
    PubMed     Text format     Abstract available


  11. ABDELAZIZ AO, Shousha HI, Said EM, A Soliman Z, et al
    Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2018 Jul 17. doi: 10.1097/MEG.0000000000001196.
    PubMed     Text format     Abstract available


  12. SOLUND C, Andersen ES, Mossner B, Laursen AL, et al
    Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
    Eur J Gastroenterol Hepatol. 2018 Jul 9. doi: 10.1097/MEG.0000000000001192.
    PubMed     Text format     Abstract available


  13. HILL LA, Delmonte RJ, Andrews B, Richards L, et al
    Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Jul 2. doi: 10.1097/MEG.0000000000001195.
    PubMed     Text format     Abstract available


  14. ALAVIAN SM, Sharafi H
    Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'.
    Eur J Gastroenterol Hepatol. 2018;30:807-808.
    PubMed     Text format    


  15. OZCELIK F, Sertoglu E
    Povital role of platelet count in platelet-lymphocyte count used in distinguishing patients with significant liver fibrosis and insulin resistance.
    Eur J Gastroenterol Hepatol. 2018;30:807.
    PubMed     Text format    


    June 2018
  16. VIEJO LG, Herola AG, Lloret IS, Ruano FS, et al
    Screening of hepatitis C virus infection in adult general population in Spain.
    Eur J Gastroenterol Hepatol. 2018 Jun 22. doi: 10.1097/MEG.0000000000001190.
    PubMed     Text format     Abstract available


  17. AGUILERA A, Rodriguez-Calvino J, de Mendoza C, Soriano V, et al
    Hepatitis delta in patients with resolved hepatitis B virus infection.
    Eur J Gastroenterol Hepatol. 2018 Jun 20. doi: 10.1097/MEG.0000000000001187.
    PubMed     Text format     Abstract available


  18. SHANMUGAM RP, Balakrishnan S, Varadhan H, Shanmugam V, et al
    Prevalence of hepatitis B and hepatitis C infection from a population-based study in Southern India.
    Eur J Gastroenterol Hepatol. 2018 Jun 8. doi: 10.1097/MEG.0000000000001180.
    PubMed     Text format     Abstract available


    May 2018
  19. YOON CH, Jin YJ, Lee JW
    Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area.
    Eur J Gastroenterol Hepatol. 2018 May 29. doi: 10.1097/MEG.0000000000001174.
    PubMed     Text format     Abstract available


  20. ISAKOV V, Paduta D, Viani RM, Enejosa JV, et al
    Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Eur J Gastroenterol Hepatol. 2018 May 14. doi: 10.1097/MEG.0000000000001166.
    PubMed     Text format     Abstract available


  21. AGUILERA A, Trastoy R, Rodriguez-Calvino J, Manso T, et al
    Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain.
    Eur J Gastroenterol Hepatol. 2018 May 8. doi: 10.1097/MEG.0000000000001163.
    PubMed     Text format     Abstract available


  22. CHEN B, Wang YH, Qian JQ, Wu DB, et al
    Human mesenchymal stem cells for hepatitis B virus-related acute-on-chronic liver failure: a systematic review with meta-analysis.
    Eur J Gastroenterol Hepatol. 2018 May 3. doi: 10.1097/MEG.0000000000001156.
    PubMed     Text format     Abstract available


  23. TACHI Y, Hirai T, Kojima Y, Ishizu Y, et al
    Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 May 2. doi: 10.1097/MEG.0000000000001159.
    PubMed     Text format     Abstract available


  24. HUANG R, Wang J, Xia J, Hao Y, et al
    Platelets-to-lymphocyte ratio as a predictor of liver fibrosis and insulin resistance in hepatitis C virus infection: more evidence is needed.
    Eur J Gastroenterol Hepatol. 2018;30:583.
    PubMed     Text format    


  25. HASSANY M, Elsharkawy A, Maged A, Mehrez M, et al
    Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001152.
    PubMed     Text format     Abstract available


  26. FOUAD R, Elbaz T, Abdel Alem S, Elsharkawy A, et al
    Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001151.
    PubMed     Text format     Abstract available


    April 2018
  27. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001145.
    PubMed     Text format     Abstract available


  28. SPAHR L, Goossens N, Furrer F, Dupuis M, et al
    A return to harmful alcohol consumption impacts on portal hemodynamic changes following alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001148.
    PubMed     Text format     Abstract available


  29. GOKCE O, Ozenirler S, Atak Yucel A, Oruklu N, et al
    Evaluation of serum procollagen C-proteinase enhancer 1 level as a fibrosis marker in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2018 Apr 20. doi: 10.1097/MEG.0000000000001123.
    PubMed     Text format     Abstract available


  30. JIN CN, Chen JD, Sheng JF
    Vitamin D deficiency in hepatitis C virus infection: what is old? what is new?
    Eur J Gastroenterol Hepatol. 2018 Apr 16. doi: 10.1097/MEG.0000000000001134.
    PubMed     Text format     Abstract available


  31. SPINICCI M, Emmi G, Dies L, Barilaro A, et al
    Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases.
    Eur J Gastroenterol Hepatol. 2018 Apr 11. doi: 10.1097/MEG.0000000000001132.
    PubMed     Text format     Abstract available


  32. SU YC, Lin PC, Yu HC, Wu CC, et al
    Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Eur J Gastroenterol Hepatol. 2018 Apr 4. doi: 10.1097/MEG.0000000000001130.
    PubMed     Text format     Abstract available


  33. EFE C, Ozaslan E, Purnak T
    Second-line immunosuppressants for autoimmune hepatitis.
    Eur J Gastroenterol Hepatol. 2018;30:490-491.
    PubMed     Text format    


    February 2018
  34. KOBAYASHI N, Iijima H, Tada T, Kumada T, et al
    Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 Feb 28. doi: 10.1097/MEG.0000000000001106.
    PubMed     Text format     Abstract available


  35. PYRSOPOULOS N, Trilianos P, Lingiah VA, Fung P, et al
    The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
    Eur J Gastroenterol Hepatol. 2018 Feb 23. doi: 10.1097/MEG.0000000000001101.
    PubMed     Text format     Abstract available


  36. SAGNELLI E, Stroffolini T, Sagnelli C, Cacopardo B, et al
    Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
    Eur J Gastroenterol Hepatol. 2018 Feb 20. doi: 10.1097/MEG.0000000000001099.
    PubMed     Text format     Abstract available


  37. ZHANG Y, Shi Y, Wu R, Wang X, et al
    Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients.
    Eur J Gastroenterol Hepatol. 2018 Feb 16. doi: 10.1097/MEG.0000000000001100.
    PubMed     Text format     Abstract available


  38. HUANG R, Zhao XA, Wang J, Hao Y, et al
    Simple noninvasive tests for the detection of advanced liver fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2018;30:241.
    PubMed     Text format    


  39. ZHANG X, Qi X, Yoshida EM, Mendez-Sanchez N, et al
    Ischemic stroke in liver cirrhosis: epidemiology, risk factors, and in-hospital outcomes.
    Eur J Gastroenterol Hepatol. 2018;30:233-240.
    PubMed     Text format     Abstract available


    January 2018
  40. ADHOUTE X, Penaranda G, Raoul JL, Sellier F, et al
    Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2018 Jan 30. doi: 10.1097/MEG.0000000000001082.
    PubMed     Text format     Abstract available


  41. LULLAU A, Petroff D, Batz O, Kramer J, et al
    Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting.
    Eur J Gastroenterol Hepatol. 2018 Jan 10. doi: 10.1097/MEG.0000000000001052.
    PubMed     Text format     Abstract available


  42. PANG Q, Zhou L, Qu K, Cui RX, et al
    Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study.
    Eur J Gastroenterol Hepatol. 2018;30:60-70.
    PubMed     Text format     Abstract available


    December 2017
  43. ROULOT D, Thibault V, Laforest C, Fontaine H, et al
    Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    Eur J Gastroenterol Hepatol. 2017 Dec 21. doi: 10.1097/MEG.0000000000001035.
    PubMed     Text format     Abstract available


  44. ALSEBAEY A, Elhelbawy M, Waked I
    Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease.
    Eur J Gastroenterol Hepatol. 2017 Dec 13. doi: 10.1097/MEG.0000000000001013.
    PubMed     Text format     Abstract available


  45. DE LEMOS-BONOTTO M, Valle-Tovo C, Costabeber AM, Mattos AA, et al
    A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment.
    Eur J Gastroenterol Hepatol. 2017 Dec 8. doi: 10.1097/MEG.0000000000001019.
    PubMed     Text format     Abstract available


  46. BASHIR MH, Fazili J, Madhoun MF, Kanagala R, et al
    Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Dec 1. doi: 10.1097/MEG.0000000000001032.
    PubMed     Text format     Abstract available


    November 2017
  47. LIN Z, Liang J, Zhu J, Hu C, et al
    Diverse correlations between fibrosis-related factors and liver stiffness measurement by transient elastography in chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 Nov 29. doi: 10.1097/MEG.0000000000001023.
    PubMed     Text format     Abstract available


  48. MOSER S, Kozbial K, Laferl H, Schutz A, et al
    Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Eur J Gastroenterol Hepatol. 2017 Nov 8. doi: 10.1097/MEG.0000000000001027.
    PubMed     Text format     Abstract available


  49. SAAD Y, Awad A, Alakel W, Doss W, et al
    Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients.
    Eur J Gastroenterol Hepatol. 2017 Nov 2. doi: 10.1097/MEG.0000000000001008.
    PubMed     Text format     Abstract available


  50. HUANG R, Wang J, Zhao XA, Xia J, et al
    The impact of cirrhosis on the efficacy and safety of entecavir for patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017;29:1314.
    PubMed     Text format    


    October 2017
  51. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2017 Oct 23. doi: 10.1097/MEG.0000000000001004.
    PubMed     Text format     Abstract available


  52. SIMONETTI G, Gitto S, Golfieri L, Gamal N, et al
    Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients.
    Eur J Gastroenterol Hepatol. 2017 Oct 23. doi: 10.1097/MEG.0000000000000999.
    PubMed     Text format     Abstract available


  53. WIJARNPREECHA K, Chesdachai S, Jaruvongvanich V, Ungprasert P, et al
    Hepatitis C virus infection and risk of Parkinson's disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000000991.
    PubMed     Text format     Abstract available


  54. KORDA D, Lenard ZM, Gerlei Z, Jakab Z, et al
    Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000001003.
    PubMed     Text format     Abstract available


  55. ABDEL-RAZIK A, Mousa N, Zakaria S, Elhelaly R, et al
    New predictive factors of poor response to therapy in autoimmune hepatitis: role of mean platelet volume.
    Eur J Gastroenterol Hepatol. 2017 Oct 13. doi: 10.1097/MEG.0000000000000982.
    PubMed     Text format     Abstract available


  56. FAN Y, Cao W, Di H, Liu C, et al
    Assessment of liver fibrosis with acoustic radiation force impulse in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017;29:1190.
    PubMed     Text format    


    September 2017
  57. MOHAMED MS, Hanafy AS, Bassiony MAA, Hussein S, et al
    Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2017 Sep 25. doi: 10.1097/MEG.0000000000000963.
    PubMed     Text format     Abstract available


  58. TRIANTOS CK, Tsintoni A, Karaivazoglou K, Grigoropoulou X, et al
    Male hepatitis C patients' sexual functioning and its determinants.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000971.
    PubMed     Text format     Abstract available


  59. WRIGHT N, Reimer J, Somaini L, Roncero C, et al
    Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000962.
    PubMed     Text format     Abstract available


  60. LANG S, Kutting F, Staub A, Schramowski J, et al
    Performance of simple noninvasive scoring systems for the prediction of advanced fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 Sep 6. doi: 10.1097/MEG.0000000000000977.
    PubMed     Text format     Abstract available


  61. MILAZZO L, Magni C, Niero F, Schiavini M, et al
    Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.
    Eur J Gastroenterol Hepatol. 2017 Sep 4. doi: 10.1097/MEG.0000000000000965.
    PubMed     Text format     Abstract available


  62. MOUSA N, Abdel-Razik A, Farag R, Shabana W, et al
    Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    Eur J Gastroenterol Hepatol. 2017;29:1004-1009.
    PubMed     Text format     Abstract available


  63. TRIANTOS C, Kalafateli M, Aggeletopoulou I, Mandellou M, et al
    Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
    Eur J Gastroenterol Hepatol. 2017;29:998-1003.
    PubMed     Text format     Abstract available


    August 2017
  64. DOLMAZASHVILI E, Abutidze A, Chkhartishvili N, Karchava M, et al
    Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA e
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000964.
    PubMed     Text format     Abstract available


  65. SIMS OT, Guo Y, Shoreibah MG, Venkata K, et al
    Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000961.
    PubMed     Text format     Abstract available


  66. MANGLA N, Mamun R, Weisberg IS
    Viral hepatitis screening in transgender patients undergoing gender identity hormonal therapy.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000950.
    PubMed     Text format     Abstract available


  67. KARAIVAZOGLOU K, Tsermpini EE, Assimakopoulos K, Triantos C, et al
    Sexual functioning in patients with chronic hepatitis C: a systematic review.
    Eur J Gastroenterol Hepatol. 2017 Aug 22. doi: 10.1097/MEG.0000000000000949.
    PubMed     Text format     Abstract available


  68. MIOTTO N, Mendes LC, Zanaga LP, Goncales ESL, et al
    Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort.
    Eur J Gastroenterol Hepatol. 2017 Aug 10. doi: 10.1097/MEG.0000000000000944.
    PubMed     Text format     Abstract available


    July 2017
  69. POGORZELSKA J, Lapinska M, Kalinowska A, Lapinski TW, et al
    Helicobacter pylori infection among patients with liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Jul 11. doi: 10.1097/MEG.0000000000000928.
    PubMed     Text format     Abstract available


    June 2017
  70. FERNANDES SR, Marques da Costa P, Vitor S, Carvalho JR, et al
    Predicting short-term and long-term mortality of hospitalized Portuguese patients with alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2017 Jun 16. doi: 10.1097/MEG.0000000000000926.
    PubMed     Text format     Abstract available


  71. VEIGA ZST, Villela-Nogueira CA, Fernandes FF, Cavalcanti MG, et al
    Transient elastography evaluation of hepatic and spleen stiffness in patients with hepatosplenic schistosomiasis.
    Eur J Gastroenterol Hepatol. 2017;29:730-735.
    PubMed     Text format     Abstract available


    May 2017
  72. SERIGADO JM, Izzy M, Kalia H
    Novel therapies and potential therapeutic targets in the management of chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000911.
    PubMed     Text format     Abstract available


  73. STROFFOLINI T, Sagnelli E, Almasio PL, Andriulli A, et al
    Etiological factors of chronic hepatitis in Italy: a 2014 national survey.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000907.
    PubMed     Text format     Abstract available


  74. WANG PC, Wei TY, Tseng TC, Lin HH, et al
    Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000897.
    PubMed     Text format     Abstract available


  75. JABLONKA A, Solbach P, Wobse M, Manns MP, et al
    Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015.
    Eur J Gastroenterol Hepatol. 2017 May 10. doi: 10.1097/MEG.0000000000000889.
    PubMed     Text format     Abstract available


  76. HUANG R, Xia J, Liu Y, Zhang Z, et al
    Acoustic radiation force impulse in the diagnosis of liver fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000902.
    PubMed     Text format    


  77. WAHID B, Saleem K, Ali A, Rafique S, et al
    Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000895.
    PubMed     Text format    


  78. KOHLA MAS, Abbasy M, Abozeid M, El-Abd O, et al
    Assessment of liver fibrosis with acoustic radiation force impulse imaging versus liver histology in patients with chronic hepatitis C: a pilot study.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000903.
    PubMed     Text format     Abstract available


  79. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017;29:509-515.
    PubMed     Text format     Abstract available


  80. IINO C, Shimoyama T, Igarashi T, Aihara T, et al
    Usefulness of the Glasgow-Blatchford score to predict 1-week mortality in patients with esophageal variceal bleeding.
    Eur J Gastroenterol Hepatol. 2017;29:547-551.
    PubMed     Text format     Abstract available


  81. SOURIANARAYANANE A, Talluri J, Humar A, McCullough AJ, et al
    Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis.
    Eur J Gastroenterol Hepatol. 2017;29:516-523.
    PubMed     Text format     Abstract available


    April 2017
  82. CORDERO-RUIZ P, Carmona-Soria I, Rodriguez-Tellez M, Caunedo-Alvarez A, et al
    Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
    Eur J Gastroenterol Hepatol. 2017 Apr 25. doi: 10.1097/MEG.0000000000000886.
    PubMed     Text format     Abstract available


  83. MARCELLIN F, Protopopescu C, Esterle L, Wittkop L, et al
    Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).
    Eur J Gastroenterol Hepatol. 2017 Apr 17. doi: 10.1097/MEG.0000000000000883.
    PubMed     Text format     Abstract available


  84. TABERNILLA A, Grandal M, Pernas B, Castro-Iglesias A, et al
    Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Eur J Gastroenterol Hepatol. 2017 Apr 13. doi: 10.1097/MEG.0000000000000882.
    PubMed     Text format     Abstract available


    March 2017
  85. SHERIGAR JM, Gayam V, Khan A, Mukhtar O, et al
    Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017 Mar 24. doi: 10.1097/MEG.0000000000000871.
    PubMed     Text format     Abstract available


  86. JI F, Tian C, Li Z, Deng H, et al
    Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older.
    Eur J Gastroenterol Hepatol. 2017 Mar 21. doi: 10.1097/MEG.0000000000000873.
    PubMed     Text format    


  87. MURATORI P, Efe C, Muratori L, Ozaslan E, et al
    Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study.
    Eur J Gastroenterol Hepatol. 2017 Mar 21. doi: 10.1097/MEG.0000000000000870.
    PubMed     Text format     Abstract available


  88. TANWAR S, Trembling PM, Hogan BJ, Srivastava A, et al
    Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
    Eur J Gastroenterol Hepatol. 2017;29:289-296.
    PubMed     Text format     Abstract available


    February 2017
  89. LIONCO LC, de Mattos AA, Horbe AF, Costabeber AM, et al
    Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil.
    Eur J Gastroenterol Hepatol. 2017;29:225-230.
    PubMed     Text format     Abstract available


    January 2017
  90. ZHU S, Waili Y, Qi X, Chen Y, et al
    Lymphocyte-monocyte ratio at admission predicts possible outcomes in patients with acute-on-chronic liver failure.
    Eur J Gastroenterol Hepatol. 2017;29:31-35.
    PubMed     Text format     Abstract available


  91. PAPADOPOULOS N, Deutsch M, Manolakopoulos S, Bitsi C, et al
    Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Eur J Gastroenterol Hepatol. 2017;29:56-60.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: